Thermo Fisher Scientific Human CEACAM5 (CD66e) Recombinant Protein

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Immunohistochemistry (IHC)

Assay-dependent

-

ELISA (ELISA)

Assay-dependent

-

Functional Assay (Functional)

Assay-dependent

-

Product Specifications

Species

Human

Expression System

HEK293 cells

Amino acid sequence

Human CEACAM5, amino acids Met1-Ala685 (Accession # NP_004354.2) with a C-terminal His-tag

Tag

His-tag

Molecular weight

72.8 kDa

Class

Recombinant

Type

Protein

Purity

≥95 % as determined by SDS-PAGE. ≥95 % as determined by SEC-HPLC.

Endotoxin concentration

<1.0 EU/µg

Activity

1.Loaded Anti-Human CEACAM5 antibody, human IgG1 on ProA Biosensor, can bind Human CEACAM5 (CD66e) Recombinant Protein with an affinity constant of 3.72 nM as determined in a BLI assay (Sartorius Octet Red384) (Routinely tested).
2.Immobilized Anti-CEA Antibody at 2 µg/mL (100 µL/well) can bind Human CEACAM5 (CD66e) Recombinant Protein, The EC50 is 5.5-16 ng/mL.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Storage buffer

20mM tris, pH 8, with 5% mannitol, 5% trehalose, 150mM NaCl, 0.01% Tween 80

Contains

no preservative

Storage conditions

-20°C or -80°C if preferred

Shipping conditions

Ambient

Product Specific Information

Reconstitution: Dissolve the protein in sterile double distilled water to a concentration of 0.2 mg/mL or lower. It is recommended that the protein be aliquoted and be used as soon as possible. Store aliquots under sterile conditions at -20°C. Avoid repeated freeze-thaw cycles.

Target Information

CEA (Carcino Embryonic Antigen, CD66e) is synthesized during development in the fetal gut, and re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is a member of carcinoembryonic antigens, immunoglobulin supergene family and consists of a single N domain (structural homology to the immunoglobulin variable) and six immunoglobulin constant-like A (A1, A2, A3) and B domains (B1, B2, B3). Antibodies to CEA are useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60 to 70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). CEA is a member of a large family of glycoproteins, a useful tumor marker for adenocarcinoma, and found in adenocarcinomas of endodermally derived digestive system epithelium and fetal colon. Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster. CEA was originally described in bile ducts of liver as biliary glycoprotein. Subsequently, CEA was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The encoded protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup. Multiple cellular activities have been attributed to the encoded protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses. Multiple transcript variants encoding different isoforms have been reported, but the full-length nature of all variants has not been defined.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.